Use of Activated Recombinant Human Factor VII in Cardiac Surgery
| Status: | Terminated |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/13/2017 |
| Start Date: | August 2004 |
| End Date: | November 2007 |
A Multi-centre, Randomised, Double-blind, Placebocontrolled, Dose Escalation Trial on Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Post-operative Bleeding in Patients Following Cardiac Surgery Requiring Cardiopulmonary Bypass
This trial is conducted in Africa, Asia, Europe, South America and the United States of
America (USA).
The trial is planned to investigate the safety and efficacy of NovoSeven® in the management
of post-operative bleeding in patients following cardiac surgery.
America (USA).
The trial is planned to investigate the safety and efficacy of NovoSeven® in the management
of post-operative bleeding in patients following cardiac surgery.
Inclusion Criteria:
- Post-operative bleeding according to pre-defined criteria for critical bleeding
We found this trial at
18
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials